Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SCD411 vs Eylea in neovascular age-related macular degeneration
jRCT2041210008Phase 3Completed
- Sponsor
- Sam Chun Dang Pharm Co., Ltd.
- Start
- Nov 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of SCD411 in exudative macular degeneration (2 arms), sponsored by Sam Chun Dang Pharm Co., Ltd. Started Nov 2020; status: completed.
02
Drugs
SCD411
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2041210008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210008.